UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 135

Sortiert nach

Endocrine‐Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management

The oncologist (Dayton, Ohio), 2020-04, Vol.25 (4), p.290-300

2020

Volltextzugriff (PDF)

Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations

Journal for immunotherapy of cancer, 2018-12, Vol.6 (1), p.141-141, Article 141

2018

Volltextzugriff (PDF)

A Randomized Phase II Trial of mFOLFOX6 + Bevacizumab Alone or with AdCEA Vaccine + Avelumab Immunotherapy for Untreated Metastatic Colorectal Cancer

The oncologist (Dayton, Ohio), 2022-03, Vol.27 (3), p.198-209

2022

Volltextzugriff (PDF)

Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies

Journal for immunotherapy of cancer, 2020-12, Vol.8 (2), p.e001395

2020

Volltextzugriff (PDF)

Perspectives on the clinical development of immunotherapy in prostate cancer

Asian journal of andrology, 2018-05, Vol.20 (3), p.253-259

2018

Volltextzugriff (PDF)

First-line pembrolizumab plus androgen deprivation therapy for locally advanced microsatellite instability-high prostate cancer in a patient with Muir-Torre syndrome: A case report

Frontiers in oncology, 2023-03, Vol.13, p.1126476

2023

Volltextzugriff (PDF)

Improving the Odds in Advanced Breast Cancer With Combination Immunotherapy: Stepwise Addition of Vaccine, Immune Checkpoint Inhibitor, Chemotherapy, and HDAC Inhibitor in Advanced Stage Breast Cancer

Frontiers in oncology, 2021-03, Vol.10, p.581801-581801

2021

Volltextzugriff (PDF)

Relugolix in Clinical Practice: The Best Route for All?

The oncologist (Dayton, Ohio), 2023-08, Vol.28 (8), p.647-650

2023

Volltextzugriff (PDF)

The Dietary Supplement Health And Education Act: are we healthier and better informed after 27 years?

The lancet oncology, 2021-07, Vol.22 (7), p.915-916

2021

Volltextzugriff (PDF)

Neurotoxicities associated with checkpoint inhibitors: Two case reports and a review of the literature

Clinical case reports, 2020-01, Vol.8 (1), p.24-32

2020

Volltextzugriff (PDF)

Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trials

The Lancet (British edition), 2022-08, Vol.400 (10351), p.512-521

2022

Volltextzugriff (PDF)

A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules

Clinical cancer research, 2019-08, Vol.25 (16), p.4933-4944

2019

Volltextzugriff (PDF)

A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)‐Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer

The oncologist (Dayton, Ohio), 2020-06, Vol.25 (6), p.479-e899

2020

Volltextzugriff (PDF)

Enzalutamide Monotherapy in the EMBARK Trial Should Be Practice-changing and Existing Data Suggest How to Mitigate Toxicity

European urology oncology, 2024-06

2024

Volltextzugriff (PDF)

Trends in Grade 5 Toxicity and Response in Phase I Trials in Hematologic Malignancy: 20-Year Experience From the Cancer Therapy Evaluation Program at the National Cancer Institute

Journal of clinical oncology, 2022-06, Vol.40 (17), p.1949-1957

2022

Volltextzugriff (PDF)

A Single-arm Phase II Study Combining NLG207, a Nanoparticle Camptothecin, with Enzalutamide in Advanced Metastatic Castration-resistant Prostate Cancer Post-Enzalutamide

The oncologist (Dayton, Ohio), 2022-09, Vol.27 (9), p.718-e694

2022

Volltextzugriff (PDF)

Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic Response

Clinical cancer research, 2021-01, Vol.27 (2), p.429-437

2021

Volltextzugriff (PDF)

Docetaxel extravasation: Pathologic correlation and treatment with intralesional steroids

JAAD Case Reports, 2017-07, Vol.3 (4), p.322-325

2017

Volltextzugriff (PDF)

Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single‐Dose Administration Under Fasting Conditions in Prostate Cancer

The oncologist (Dayton, Ohio), 2021-09, Vol.26 (9), p.729-e1493

2021

Volltextzugriff (PDF)

Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumors

Cancer chemotherapy and pharmacology, 2020-10, Vol.86 (4), p.475-486

2020

Volltextzugriff (PDF)

Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer

Journal for immunotherapy of cancer, 2020-03, Vol.8 (1), p.e000655

2020

Volltextzugriff (PDF)

Phase 2 Study of Seviteronel (INO-464) in Patients With Metastatic Castration-Resistant Prostate Cancer After Enzalutamide Treatment

Clinical genitourinary cancer, 2020-08, Vol.18 (4), p.258-267.e1

2020

Volltextzugriff (PDF)

1 – 25 von 135

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SeriePlos One

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(128)
Mit Volltextzugriff
(133)

Publikationsform

Sprache

Englisch
(135)
Japanisch
(9)

Erscheinungsjahr

n.n

Thema

Science & Technology
(56)
Life Sciences & Biomedicine
(50)
Oncology
(31)
Humans
(30)
Male
(20)
Female
(14)
Middle Aged
(13)
Prostate Cancer
(13)
Immunotherapy
(12)
Metastasis
(12)
Aged
(10)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(8)
Cancer
(7)
Clinical Trials
(7)
Tumors
(7)
Urology & Nephrology
(7)
Cancer Therapies
(6)
Chemotherapy
(6)
Drug Therapy
(6)
Immunology
(6)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Endocrine‐Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management

Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations

A Randomized Phase II Trial of mFOLFOX6 + Bevacizumab Alone or with AdCEA Vaccine + Avelumab Immunotherapy for Untreated Metastatic Colorectal Cancer

Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies

Perspectives on the clinical development of immunotherapy in prostate cancer

First-line pembrolizumab plus androgen deprivation therapy for locally advanced microsatellite instability-high prostate cancer in a patient with Muir-Torre syndrome: A case report

Improving the Odds in Advanced Breast Cancer With Combination Immunotherapy: Stepwise Addition of Vaccine, Immune Checkpoint Inhibitor, Chemotherapy, and HDAC Inhibitor in Advanced Stage Breast Cancer

Relugolix in Clinical Practice: The Best Route for All?

Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors

The Dietary Supplement Health And Education Act: are we healthier and better informed after 27 years?

Neurotoxicities associated with checkpoint inhibitors: Two case reports and a review of the literature

Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial

Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trials

A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules

A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)‐Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer

Enzalutamide Monotherapy in the EMBARK Trial Should Be Practice-changing and Existing Data Suggest How to Mitigate Toxicity

Trends in Grade 5 Toxicity and Response in Phase I Trials in Hematologic Malignancy: 20-Year Experience From the Cancer Therapy Evaluation Program at the National Cancer Institute

Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer

A Single-arm Phase II Study Combining NLG207, a Nanoparticle Camptothecin, with Enzalutamide in Advanced Metastatic Castration-resistant Prostate Cancer Post-Enzalutamide

Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic Response

Docetaxel extravasation: Pathologic correlation and treatment with intralesional steroids

Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single‐Dose Administration Under Fasting Conditions in Prostate Cancer

Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumors

Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer

Phase 2 Study of Seviteronel (INO-464) in Patients With Metastatic Castration-Resistant Prostate Cancer After Enzalutamide Treatment

Aktive Filter

Suchergebnisse filtern